Adolfo Garcia-Sastre, PhD
img_Adolfo Garcia-Sastre
PROFESSOR | Microbiology
PROFESSOR | Medicine, Infectious Diseases
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Antivirals, Biodefense, Cellular Immunity, Cytokines, Gene Expressions, Gene Regulation, Gene Therapy, Immune Antagonism, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Interferon Resistance, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, RNA Transport & Localization, Trafficking, Transcription Factors, Transcriptional Activation and Repression, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Immunology [IMM], Microbiology [MIC]
The Garcia-Sastre Laboratory is focused on exploring virus-host interactions with an emphasis on virus regulation of innate and adaptive immune responses. The outcome of these interactions not only determines disease severity but also influences the development of protective immunity resulting from viral infection and/or vaccination. The team has developed several techniques (reverse genetics), which allow for the genetic manipulation of the genomes of several virus families including influenza virus and Newcastle disease virus. Other viruses being studied include Zika virus, Dengue virus, West Nile virus, and Crimean-Congo hemorrhagic fever virus. These techniques are currently being used in several research areas including: i) characterization of virus-encoded virulence factors, ii) identification of virus-encoded antagonists of the interferon system, iii) virus replication and gene expression, iv) immune regulation of influenza replication, and v) vaccine development. Reverse genetics are also being utilized to generate virus vectors based on influenza virus and Newcastle disease virus. These viruses are effective inducers of humoral and cellular immune responses. Live attenuated influenza virus vaccines are being generated by genetic modification of the influenza virus-encoded interferon antagonist that was originally identified by the laboratory. Also, recombinant viruses can be produced that express protective antigens of other pathogens for which no safe attenuated vaccine strains are available.

PhD, University of Salamanca

Adolfo Garcia-Sastre, PhD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Garcia-Sastre during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • Vaxalto
  • Pagoda Genomics


  • 7 Hills Pharma LLC
  • Vaxalto
  • Avimex
  • PharmaMar (Zeltia Group)
  • Esperovax Inc
  • Applied Biological Laboratories Inc
  • Farmak International Holding
  • Paratus

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Accurius
  • Vaxalto
  • Curelab Veterinary
  • CureLab Oncology
  • Pagoda
  • Vivaldi Biosciences Inc.

Royalty Payments:

  • Merck & Co., Inc.
  • Avimex
  • MedImmune, LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.